Recent 8-K filings for INTI

• April 1, 2026, 7:59 PM ET other material materiality 0.50 neutral item 8.01item 9.01

  Inhibitor Therapeutics provides update on itraconazole PK study; plans global patent filing for amorphous formulation

  Top-line PK results from three-way crossover study expected after May 1, 2026; Periods 2 and 3 scheduled for April 10 and 24.

• April 1, 2026, 7:59 PM ET litigation materiality 0.70 negative item 7.01item 9.01

  Inhibitor Therapeutics sues investor for failing to close $3M financing

  Filed suit March 30, 2026 against an institutional investor for breach of the Securities Purchase Agreement.

• February 24, 2026, 6:59 PM ET other material materiality 0.60 neutral item 1.01item 9.01 ◈ Material Agreements

  Inhibitor Therapeutics enters $3M private placement; sells 12M shares and warrants

  Company to sell 12,000,000 shares of common stock at $0.25/share to an institutional investor, raising $3M.

• October 27, 2025, 7:59 PM ET other material materiality 0.50 neutral item 1.01item 5.02item 9.01

  Inhibitor Therapeutics enters Frameshift consulting pact for Gorlin syndrome; 18M warrants possible

  Entered Master Services Agreement with Frameshift Management for biostatistics, regulatory, and business development support for itraconazole program in Gorlin's syndrome.

Materiality & sentiment trend

Max materiality 0.70 · Median 0.55 · Most common event other_material

0 positive 1 negative 3 neutral

source · INTI on sec.gov